Ke Wen Cai
Chief Executive Officer at Geneception, Inc.
Profile
Amber Cai is a Venture Partner with F-Prime Capital, focusing on early-stage biotechnology investments.
She is the founding CEO of Geneception, a leading gene and cell therapy company.
Prior to joining Geneception, Amber was a founding member of Novartis’ R&D Center in China, where she was most recently the Head of Operations and led the Center’s overall business operations overseeing a broad set of functions.
During 2005-2006, Amber led the efforts to establish Novartis’ R&D presence in China from the concept stage to implementation.
After the Center was established in 2006 as the first fully integrated research and development center in China by multinational pharma companies, she played an instrumental role in recruiting talent, establishing operations, developing Novartis’ China R&D strategy, and building strategic partnerships with government and other external stakeholders and collaborators.
Prior to her work in China, Amber was with the Business Development at Novartis Institutes for BioMedical Researches in Cambridge, MA.
Amber has decades of experience in science before shifting her career into business.
She completed her Ph.D.
at Massachusetts Institute of Technology in GPCR signaling and holds an MBA degree from MIT Sloan School of Management.
Ke Wen Cai active positions
Companies | Position | Start |
---|---|---|
Geneception, Inc.
Geneception, Inc. BiotechnologyHealth Technology Geneception, Inc. provides healthcare services. The company is headquartered in Cambridge, MA. | Chief Executive Officer | - |
Impresa Management LLC
Impresa Management LLC Investment ManagersFinance Impresa Management LLC(Impresa Management) is a Private Equity/Venture Capital firm, a subsidiary of Devonshire Investors LLC founded in 1946.The firm is headquartered in Boston. | Private Equity Investor | - |
Skyline Therapeutics (Shanghai) Co., Ltd.
Skyline Therapeutics (Shanghai) Co., Ltd. BiotechnologyHealth Technology Part of Skyline Therapeutics (Hong Kong) Ltd., Skyline Therapeutics (Shanghai) Co., Ltd. is a fully Chinese integrated gene therapy company. The company is based in Shanghai, China. Skyline Therapeutics is dedicated to the discovery, development, and delivery of innovative therapies. The company was founded in 2019. The CEO is Ke Wen Cai. | Chief Executive Officer | - |
Training of Ke Wen Cai
Massachusetts Institute of Technology | Doctorate Degree |
MIT Sloan School of Management | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 3 |
---|---|
Impresa Management LLC
Impresa Management LLC Investment ManagersFinance Impresa Management LLC(Impresa Management) is a Private Equity/Venture Capital firm, a subsidiary of Devonshire Investors LLC founded in 1946.The firm is headquartered in Boston. | Finance |
Geneception, Inc.
Geneception, Inc. BiotechnologyHealth Technology Geneception, Inc. provides healthcare services. The company is headquartered in Cambridge, MA. | Health Technology |
Skyline Therapeutics (Shanghai) Co., Ltd.
Skyline Therapeutics (Shanghai) Co., Ltd. BiotechnologyHealth Technology Part of Skyline Therapeutics (Hong Kong) Ltd., Skyline Therapeutics (Shanghai) Co., Ltd. is a fully Chinese integrated gene therapy company. The company is based in Shanghai, China. Skyline Therapeutics is dedicated to the discovery, development, and delivery of innovative therapies. The company was founded in 2019. The CEO is Ke Wen Cai. | Health Technology |
- Stock Market
- Insiders
- Ke Wen Cai